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Osteoarthritis is becoming more problematic as the
population ages. Recent reports suggest that the
benefit of anti-inflammatory drugs is unimpressive and
the incidence of side effects is worrying. Low-level laser
(light) therapy (LLLT) is an alternative approach with no
known side effects and with reports of substantial
therapeutic efficacy in osteoarthritis. In this issue of
Arthritis Research & Therapy, Alves and colleagues used
a rat model of osteoarthritis produced by intra-articular
injection of the cartilage-degrading enzyme papain to
test 810-nm LLLT. A single application of LLLT
produced significant reductions in inflammatory cell
infiltration and inflammatory cytokines 24 hours later. A
lower laser power was more effective than a higher
laser power. However, more work is necessary before
the title question can be answered in the affirmative.overall benefit compared with lower doses of LLLT [6].In this issue of Arthritis Research & Therapy, Alves and
colleagues [1] reported an interesting preclinical study
suggesting that near-infrared light applied to the rat
knee has significant benefits on joint inflammation in an
animal model of osteoarthritis. One in every two persons
in the US will experience some form of osteoarthritis in
their lifetime, and the incidence is 80% in those over 75
[2]. Treatment is with analgesics (acetaminophen), non-
steroidal anti-inflammatory drugs (NSAIDs) (ibuprofen
and diclofenac), and COX2 inhibitors (Celebrex, Pfizer
Inc., New York, NY, USA), but these therapies have sig-
nificant risks of adverse effects, such as gastrointestinal
bleeding with NSAIDs and myocardial infarction with
COX2 inhibitors [3]. Low-level laser (light) therapy
(LLLT) is a rapidly growing alternative approach to
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tion of tissue death after injury or infarction [4]. The red
or near-infrared photons are absorbed in cytochrome c
oxidase (unit IV of the mitochondrial respiratory chain),
thereby increasing mitochondrial respiration and ATP
production and initiating signaling pathways mediated
by reactive oxygen species, nitric oxide, and cyclic AMP,
ultimately leading to activation of several transcription
factors [5]. A large number of studies have examined the
anti-inflammatory effects of LLLT and have reported re-
ductions in inflammatory cell (neutrophils, macro-
phages, lymphocytes, and mast cells) infiltration in
multiple pathologies and have shown reductions in sev-
eral inflammatory cytokines, such as ILs and TNF-α.
Many observers have reported that there is a biphasic
dose response that operates in LLLT, and this means that
increasing the total energy or the rate of energy delivery
(power density) may be counterproductive, giving less
LLLT has been used clinically in osteoarthritis for many
years but is still considered controversial. Although a
Cochrane review [7] reported mixed and conflicting re-
sults, a subsequent analysis conducted by Bjordal and
colleagues concluded that ‘the Cochrane review conclu-
sion was neither robust nor valid. Further sensitivity
analyses with inclusion of valid non-included trials, per-
formance of missing follow-up, and subgroup analyses
revealed consistent and highly significant results in favor
of active LLLT for osteoarthritis’ [8]. This disagreement
in the literature suggests that much more work compris-
ing animal studies, clinical trials, and systematic reviews
will need to be done before LLLT becomes accepted as a
valid therapy.
Alves and colleagues [1] used a clinically relevant
model of osteoarthritis in which the proteolytic enzyme
papain is injected into the rat knee joint, where it de-
grades the cartilage, thus causing inflammation. The
knees received a single application of 4 J of energy from
an 808-nm laser to the medial and lateral aspects of the
knee, delivered at either 50 or 100 mW, and the rats
were sacrificed after 24 hours. The authors found a
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synovial washing with both power levels but a bigger
reduction in macrophages at the 50-mW power level.
Reductions in IL-1β and IL-6 mRNA were found, with
50 mW being better than 100 mW, whereas a bigger
reduction in TNF-α was seen with 100 mW. The
authors hypothesized that the twice-longer illumination
time needed to deliver the same energy at half the power
may have been responsible for the better effect of the
50-mW laser application, and this agrees with a previous
study that examined zymosan-induced arthritis in the
rat knee [9] and found that a longer illumination time
was more effective. Previous work from this group [10]
had shown that LLLT in the same model increased
angiogenesis and the amount of squamous epithelium
while decreasing fibrosis in the joint. These results pro-
vide additional justification for the use of LLLT (espe-
cially near-infrared laser that has the tissue penetration
required for joints) as a treatment for osteoarthritis.
Nevertheless, it should be pointed out that the study
was only an animal model, not a clinical study in human
disease, and further studies will be necessary to define
the benefits of LLLT in osteoarthritis. In addition to the
demonstrated anti-inflammatory effects, LLLT may have
benefits provided by its ability to act on nerves by redu-
cing pain transmission and activating endogenous opioid
receptors [11].
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